Monday, September 5, 2022 Daily Archives

Horizon doubling down on Irish biomanufacturing with drug substance plant

by

Horizon Therapeutics will build a second facility in Waterford, Ireland to support its rare disease biologics portfolio. In June 2021, Horizon acquired a 44,000 square-foot drug product manufacturing facility from OPKO health’s EirGen Pharma for $65 million. This first step into building a biomanufacturing network for horizon followed the launch of Tepezza (teprotumumab), a monoclonal antibody for thyroid eye disease, and off the back of growing sales of gout treatment Krystexxa (pegloticase). Having tested the waters, the firm will now…

September 5, 2022

TCR² lauds positive work culture to overcome staff bottlenecks

by

T-cell receptor firm TCR² Therapeutics told delegates at Advanced Therapies Europe it is key to embed culture into your employees to attract and retain talent in the life science space. Angela Justice, chief people officer at TCR², told attendees that the key three ways to scale your culture lie in “anchor[ing] your culture through the employee life cycle, focus[ing] on retention, and find[ing] your force multipliers.’ Justice noted that a challenge of anchoring culture typically derives from the values of…

September 5, 2022